NBTX

Nanobiotix
NBTX

Overview Fund Trends Analyst Outlook Journalist POV
20.87 USD
+2.43
13.18%
At close Updated Oct 31, 4:00 PM EDT
Pre-market
After hours
19.21
--1.66
7.95%
1 day
13.18%
5 days
22.91%
1 month
10.48%
3 months
202.46%
6 months
515.63%
Year to date
619.66%
1 year
401.68%
5 years
22.91%
10 years
22.91%
 

About: Nanobiotix SA is a clinical-stage biotechnology company that has one operating segment, which focuses on developing product candidates that use its proprietary nanotechnology to transform cancer treatment by increasing the efficacy of radiotherapy. The company develops NanoXray products to help patients receiving radiotherapy by magnifying the effect of radiotherapy within tumor cells without increasing the dose to surrounding healthy tissues. Its product candidate is NBTXR3, a preclinical research program for cancer immunotherapies.

Employees: 103

Healthcare Biotechnology
0
Funds holding %
of 7,505 funds
Explore Fund Trends
–
Analysts bullish %
See Analyst Outlook
–
Positive news %
Check Journalist POV
Price charts implemented using Lightweight Charts™